Strong Earnings Per Share
Aflac reported net earnings per diluted share of $3.08 and adjusted earnings per diluted share of $2.49 for Q3 2025, a 15.3% increase year-over-year.
Significant Growth in Japan
Aflac Japan experienced an 11.8% year-over-year sales increase, with a 42% increase in cancer insurance sales driven by the Miraito product.
Capital Deployment
Aflac deployed a record $1 billion in capital to repurchase 9.3 million shares and paid dividends of $309 million, returning $1.3 billion to shareholders in Q3 2025.
Strong Performance in U.S. Buy-to-Build Initiatives
The U.S. segment saw $390 million in new sales with a 2.8% year-over-year increase and maintained a strong premium persistency of 79%.
Milestone Achievements
2025 marks Aflac's 70th anniversary, 43 consecutive years of dividend increases, and significant anniversaries for the Aflac Cancer and Blood Disorders Center and the Aflac Duck.